RESUMEN
The ability to modulate immune responses is a major aim of many vaccine and immunotherapeutic development programs. Bromelain, a mixture of cysteine proteases, modulates immunological responses and has been proposed to be of clinical use. However, the identity of the immune cells affected by bromelain and the specific cellular functions that are altered remain poorly understood. To address these shortcomings in our knowledge, we have used both in vitro and in vivo immunological assays to study the effects of bromelain. We found that bromelain enhanced T cell receptor (TCR) and anti-CD28-mediated T cell proliferation in splenocyte cultures by increasing the costimulatory activity of accessory cell populations. However, despite increased T cell proliferation, bromelain concomitantly decreased IL-2 production in splenocyte cultures. Additionally, bromelain did not affect TCR and CD28-induced proliferation of highly purified CD4+ T cells, but did inhibit IL-2 production by these cells. In vivo, bromelain enhanced T-cell-dependent, Ag-specific, B cell antibody responses. Again, bromelain induced a concomitant decrease in splenic IL-2 mRNA accumulation in immunized mice. Together, these data show that bromelain can simultaneously enhance and inhibit T cell responses in vitro and in vivo via a stimulatory action on accessory cells and a direct inhibitory action on T cells. This work provides important insights into the immunomodulatory activity of bromelain and has important implications for the use of exogenous cysteine proteases as vaccine adjuvants or immunomodulatory agents.
Asunto(s)
Linfocitos B/inmunología , Bromelaínas/farmacología , Linfocitos T CD4-Positivos/inmunología , Activación de Linfocitos/efectos de los fármacos , Animales , Linfocitos B/efectos de los fármacos , Antígenos CD28/metabolismo , Complejo CD3/metabolismo , Linfocitos T CD4-Positivos/citología , Linfocitos T CD4-Positivos/efectos de los fármacos , División Celular , Células Cultivadas , Femenino , Técnica de Placa Hemolítica , Interleucina-2/biosíntesis , Interleucina-2/genética , Cooperación Linfocítica/efectos de los fármacos , Ratones , Ratones Endogámicos BALB C , ARN Mensajero/biosíntesis , Receptores de Antígenos de Linfocitos T/inmunología , Bazo/inmunologíaRESUMEN
Despite a large number of T cells infiltrating the liver of patients with chronic hepatitis B, little is known about their complexity or specificity. To characterize the composition of these T cells involved with the pathogenesis of chronic hepatitis B (CHB), we have studied the clonality of VbetaT cell receptor (TCR)-bearing populations in liver tissue by size spectratyping the complementarity-determining region (CDR3) lengths of TCR transcripts. We have also compared the CDR3 profiles of the lymphocytes infiltrating the liver with those circulating in the blood to see whether identical clonotypes may be detected that would indicate a virus-induced expansion in both compartments. Our studies show that in most of the patients examined, the T cell composition of liver infiltrating lymphocytes is highly restricted, with evidence of clonotypic expansions in 4 to 9 TCR Vbeta subfamilies. In contrast, the blood compartment contains an average of 1 to 3 expansions. This pattern is seen irrespective of the patient's viral load or degree of liver pathology. Although the TCR repertoire profiles between the 2 compartments are generally distinct, there is evidence of some T cell subsets being equally distributed between the blood and the liver. Finally, we provide evidence for a putative public binding motif within the CDR3 region with the sequence G-X-S, which may be involved with hepatitis B virus recognition.
Asunto(s)
Células Sanguíneas/fisiología , Hepatitis B Crónica/genética , Hepatitis B Crónica/fisiopatología , Hígado/patología , Linfocitos T/fisiología , Adolescente , Adulto , Secuencia de Aminoácidos/genética , Antígenos/fisiología , Secuencia de Bases/genética , Linfocitos T CD4-Positivos/fisiología , Linfocitos T CD8-positivos/fisiología , Células Clonales , Regiones Determinantes de Complementariedad , Femenino , Hepatitis B Crónica/patología , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia MolecularRESUMEN
Individuals with acute hepatitis B virus (HBV) infection characteristically mount a strong, multispecific cytotoxic T lymphocyte (CTL) response that is effective in eradicating virus. In contrast, this response in chronic carriers is usually weak or undetectable. Since it is generally acknowledged that HBV pathogenesis is immune-mediated, the occurrence of episodes of active liver disease in many carriers suggests that these individuals can mount active CTL responses to HBV. To see whether the detection of circulating CTLs is related to these flare episodes, we have determined the CTL precursor (CTLp) frequencies to HLA-A2-restricted viral peptides in seven patients over a 12-24-month period of their disease. Limiting dilution analyses (LDA) were performed longitudinally to five epitopes comprising the viral capsid (HBc), envelope (HBs) and polymerase (pol) proteins. Assays were performed against a mixture of peptides, or against each individual peptide, to measure overall CTL activity and the multispecificity of the responses, respectively. Since two of the patients were treated with recombinant human interleukin-12 (rHuIL-12) at the time, with one individual achieving complete disease remission a year later after being treated with interferon-alpha, we were also able to examine the effects of these cytokines on HBV cytotoxicity. Our results indicate that weak but detectable CTL responses do occur in chronic carriers which are generally associated with disease flares, although CTLps were also seen occasionally during minimal disease activity. The range of specificities varied between individuals and within each individual during the course of the disease. Finally, we also provide evidence that CTL reactivity is stimulated following treatment with certain cytokines, but is dependent on the time of administration.
Asunto(s)
Virus de la Hepatitis B/inmunología , Hepatitis B Crónica/inmunología , Interleucina-12/uso terapéutico , Linfocitos T Citotóxicos/inmunología , Adulto , Anciano , ADN Viral/sangre , Epítopos de Linfocito T/inmunología , Antígenos del Núcleo de la Hepatitis B/inmunología , Virus de la Hepatitis B/aislamiento & purificación , Hepatitis B Crónica/tratamiento farmacológico , Hepatitis B Crónica/virología , Humanos , Interferón-alfa/uso terapéutico , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/uso terapéutico , Factores de TiempoRESUMEN
Recently, it has emerged that extracellular proteases have specific regulatory roles in modulating immune responses. Proteases may act as signaling molecules to activate the Raf-1/extracellular regulated kinase (ERK)-2 pathway to participate in mitogenesis, apoptosis, and cytokine production. Most reports on the role of protease-mediated cell signaling, however, focus on their stimulatory effects. In this study, we show for the first time that extracellular proteases may also block signal transduction. We show that bromelain, a mixture of cysteine proteases from pineapple stems, blocks activation of ERK-2 in Th0 cells stimulated via the TCR with anti-CD3epsilon mAb, or stimulated with combined PMA and calcium ionophore. The inhibitory activity of bromelain was dependent on its proteolytic activity, as ERK-2 inhibition was abrogated by E-64, a selective cysteine protease inhibitor. However, inhibitory effects were not caused by nonspecific proteolysis, as the protease trypsin had no effect on ERK activation. Bromelain also inhibited PMA-induced IL-2, IFN-gamma, and IL-4 mRNA accumulation, but had no effect on TCR-induced cytokine mRNA production. This data suggests a critical requirement for ERK-2 in PMA-induced cytokine production, but not TCR-induced cytokine production. Bromelain did not act on ERK-2 directly, as it also inhibited p21ras activation, an effector molecule upstream from ERK-2 in the Raf-1/MEK/ERK-2 kinase signaling cascade. The results indicate that bromelain is a novel inhibitor of T cell signal transduction and suggests a novel role for extracellular proteases as inhibitors of intracellular signal transduction pathways.
Asunto(s)
Bromelaínas/farmacología , Inhibidores Enzimáticos/farmacología , Proteína Quinasa 1 Activada por Mitógenos/antagonistas & inhibidores , Linfocitos T/enzimología , Animales , Bromelaínas/metabolismo , Bromelaínas/toxicidad , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/inmunología , Activación Enzimática/efectos de los fármacos , Activación Enzimática/inmunología , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/toxicidad , Frutas/enzimología , Humanos , Hibridomas , Hidrólisis/efectos de los fármacos , Interleucina-2/genética , Interleucina-2/metabolismo , Células Jurkat , Ratones , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Oncogénica p21(ras)/antagonistas & inhibidores , Fosforilación/efectos de los fármacos , Tallos de la Planta/enzimología , ARN Mensajero/efectos de los fármacos , ARN Mensajero/metabolismo , Receptores de Antígenos de Linfocitos T/antagonistas & inhibidores , Receptores de Antígenos de Linfocitos T/fisiología , Linfocitos T/efectos de los fármacos , Tirosina/antagonistas & inhibidoresRESUMEN
Development of epitope-based CD8 alpha beta CTL vaccines requires effective strategies for codelivery of large numbers of individual epitopes. We have designed an artificial "polyepitope" protein containing 10 contiguous minimal CTL epitopes, which were restricted by five MHC alleles and derived from five viruses, a parasite, and a tumor model. A recombinant vaccinia virus coding for this protein was capable of inducing MHC-restricted primary CTL responses to all 10 epitopes. Mice immunized with this recombinant vaccinia showed protection against murine cytomegalovirus, Sendai virus, and a tumor model. This simple generic approach to multiepitope delivery should find application in CTL-based vaccine design.
Asunto(s)
Epítopos/genética , Epítopos/inmunología , Linfocitos T Citotóxicos/inmunología , Vacunas Sintéticas/inmunología , Secuencia de Aminoácidos , Animales , Antígenos Virales/genética , Antígenos Virales/inmunología , Diseño de Fármacos , Epítopos/administración & dosificación , Vectores Genéticos/inmunología , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Ingeniería de Proteínas/métodos , Vacunas Sintéticas/administración & dosificaciónRESUMEN
The organ of Corti and macula lagena were studied by scanning and transmission electron microscopy in two species of monotreme, the platypus and echidna. In both species, the organ of Corti had a fundamentally mammalian conformation, with distinct outer and inner hair cells, separated by a tunnel of Corti. However, unlike eutherian mammals, the monotremes had three or four rows of pillar cells, and four to five rows of inner hair cells. The organ of Corti was much shorter than in eutherian mammals, at 4.4 mm (platypus), and 7.6 mm (echidna). While the total number of outer hair cells (3,350 platypus, 5,050 echidna) was many fewer than in most eutherian mammals, the total number of inner hair cells (1,600 platypus, 2,700 echidna) was comparable with that in eutherian mammals. The stereocilia on both inner and outer hair cells underwent a systematic change in orientation across the cochlear duct, with those nearest the tunnel of Corti having their axis of symmetry oriented transversely across the duct, and those on the outer edge of the organ having the axis oriented nearly longitudinally along the duct. The macula lagena had signs of a vestibular epithelium, with tall bundles of stereocilia, a division into areas with bundles of opposing orientation and type I and type II hair cells.